

Supplementary Table S1. Antimycobacterial agents and breakpoints for testing nontuberculous mycobacteria

| Variable | Concentration range, µg/mL | MIC, µg/mL | | |
|--|----------------------------|-------------|--------------|-----------|
| | | Susceptible | Intermediate | Resistant |
| Antimicrobial agents for MAC | | | | |
| First line | | | | |
| Clarithromycin | 1–64 | ≤8 | 16 | ≥32 |
| Amikacin | 2–128 | ≤16 | 32 | ≥64 |
| Second line | | | | |
| Moxifloxacin | 0.125–8 | ≤1 | 2 | ≥4 |
| Linezolid | 1–64 | ≤8 | 16 | ≥32 |
| Antimicrobial agents for <i>M. kansasii</i> | | | | |
| First line | | | | |
| Clarithromycin | 1–64 | ≤8 | 16 | ≥32 |
| Rifampin | 0.25–16 | ≤1 | - | ≥2 |
| Second line | | | | |
| Amikacin | 2–128 | ≤16 | 32 | ≥64 |
| Ciprofloxacin | 0.25–16 | ≤1 | 2 | ≥4 |
| Doxycycline | 0.25–16 | ≤1 | 2–4 | ≥8 |
| Linezolid | 1–64 | ≤8 | 16 | ≥32 |
| Moxifloxacin | 0.125–8 | ≤1 | 2 | ≥4 |
| Linezolid | 1–64 | ≤8 | 16 | ≥32 |
| Trimethoprim/sulfamethoxazole | 0.5/9.5–32/608 | ≤2/38 | - | ≥4/76 |
| Antimicrobial agents for RGM | | | | |
| Amikacin | 2–128 | ≤16 | 32 | ≥64 |
| Cefoxitin | 4–256 | ≤16 | 32–64 | ≥128 |
| Ciprofloxacin | 0.25–16 | ≤1 | 2 | ≥4 |
| Clarithromycin | 0.25–32 | ≤2 | 4 | ≥8 |
| Doxycycline | 0.25–16 | ≤1 | 2–4 | ≥8 |
| Imipenem | 1–64 | ≤4 | 8–16 | ≥32 |
| Linezolid | 1–64 | ≤8 | 16 | ≥32 |
| Moxifloxacin | 0.125–8 | ≤1 | 2 | ≥4 |
| Trimethoprim/sulfamethoxazole | 0.5/9.5–32/608 | ≤2/38 | - | ≥4/76 |
| Tobramycin | 1–8 | ≤2 | 4 | ≥8 |

MIC: minimum inhibitory concentration; MAC: *Mycobacterium avium* complex; RGM: rapidly growing mycobacteria.